The next big opportunity in cancer treatment might be getting the immune system’s natural killer cells to fight tumors.
GT Biopharma (NASDAQ: GTBP) is developing drugs designed to point the body’s own natural killer cells at cancer.
GT Biopharma is a company developing TriKE drugs designed to activate a patient’s own natural killer cells and direct them to attack cancer.
GT Biopharma just presented new data at SITC 2026, one of the world’s most prestigious immunotherapy conferences.
In mice with pancreatic tumors, adding GT Biopharma’s TriKE drug GTB-5550 to another cancer drug got twice as many killer cells inside the tumors as that drug alone.
With the combination, tumors disappeared completely in several of the mice, the cancer was stopped from spreading, and more tumor cells died.
The first major breakthrough of immunotherapy was engineering a patient’s own T-cells to attack cancer cells.
The deal
Gilead bought Chimeric Antigen Receptor T-cell therapy leader Kite Pharma for $11.9 billion in 2017.
The approval
Kite Pharma’s Yescarta became the first Chimeric Antigen Receptor T-cell therapy approved for lymphoma in 2017.
T-cell therapies need to be custom-made, are expensive, and can cause challenging side effects for patients.
The next major opportunity in immunotherapy could be in novel drugs that activate natural killer cells.
First line of defense
Natural killer cells are the immune system’s first line of defense and can kill tumor cells on contact.
Quick to act
Unlike T-cells, natural killer cells do not need to be trained to recognize a specific target first, so they can act quickly.
The catch
Tumors can learn to slip past them, and in many solid tumors too few of them get inside.
What a TriKE does
GT Biopharma’s proprietary TriKE platform is designed to activate a patient’s natural killer cells and physically link them to cancer cells.
Instead of building a new therapy for each patient, switch on the natural killer cells they already have.
GT Biopharma is developing drugs designed to boost the cancer-killing power of a patient’s own natural killer cells, with one drug design that can be given to many patients.
There is a new wave of research and development in next-generation cancer drugs that redirect the immune system.
Oncology clinical trials
Novel modalities including cell therapies, antibody-drug conjugates and multispecific antibodies now represent roughly 35% of oncology clinical trials.
New cancer drugs
25 new cancer drugs launched globally in 2024 alone.
One platform with multiple meaningful applications.
The same TriKE design is being aimed at several cancers. GT Biopharma currently has drugs that are being studied or are cleared to be studied for prostate cancer, pancreatic cancer, multiple myeloma, and acute myeloid leukemia.
New-case estimates for the United States in 2026: American Cancer Society.
Pancreatic cancer is one of the most difficult cancers to treat.
of pancreatic cancer patients in the U.S. are alive five years after diagnosis. That is about one in seven.
Out of 100 patients, those alive five years after diagnosis
people in the U.S. are expected to be diagnosed with pancreatic cancer in 2026.
GT Biopharma’s latest study showed that adding GTB-5550 to a new pancreatic cancer drug gave stronger tumor control in mice.
University of Minnesota researchers presented the data at the SITC 2026 Annual Meeting on November 6, 2026.
more natural killer cells got inside the tumors than with the KRAS inhibitor alone.
Tumors disappeared completely in several of the mice.
The combination prevented the cancer from spreading to other organs and reduced its growth into nearby tissue.
GT Biopharma (NASDAQ: GTBP)
- Market cap
- $6.1M
- Shares outstanding
- 2.06M As of Oct 9, 2026
- Avg. daily volume (9 days)
- 81K
- Listed
- Nasdaq
Sources: Twelve Data (prices, updated after each trading day); GT Biopharma prospectus, Oct 20, 2026 (shares outstanding).
GT Biopharma is advancing multiple clinical-stage drugs designed to turn the body’s own natural killer cells against cancer.
- 1
Fresh data published at a major conference
On November 6, 2026, the company presented new GTB-5550 results at SITC 2026, one of the world’s most prestigious immunotherapy conferences.
- 2
Two drugs in human trials
GTB-3650 for blood cancers and GTB-5550 for solid tumors, including prostate and pancreatic cancer.
- 3
One platform with different applications
GT Biopharma’s TriKE design can be aimed at different types of cancers by swapping the tumor-targeting antibody fragment.
- 4
A ready-made drug
TriKE drugs work with the natural killer cells patients already have, removing the need for custom-built therapeutics for each patient.
- 5
The FDA has cleared a second GTB-5550 trial
The University of Minnesota plans to run the trial in advanced multiple myeloma.
Disclaimer
The New Money provides background information on early-stage companies from publicly available sources. The New Money provides no advice on dealing in securities, is not a financial adviser and does not hold itself out to be a financial or investment adviser. This message is meant for information and educational purposes only. The information contained in this message has not been independently verified for accuracy or completeness. Anyone interested in obtaining financial and other information on companies mentioned in this message is advised to obtain such information directly from the companies, or from their own investment adviser. The New Money does not intend for this information to be used to inform an investment decision.
The New Money has been compensated by GT Biopharma, Inc. in the amount of two hundred thousand US dollars in cash for a media campaign, which may affect our ability to be unbiased. Because The New Money is compensated to provide this coverage, the information presented is inherently one-sided and should not be considered balanced or objective. We may have long or short positions in the securities of any of the companies mentioned. We therefore stress that you should conduct extensive independent due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.
The New Money is not, and does not act as, an investment adviser, broker-dealer, or securities analyst, and is not registered with the U.S. Securities and Exchange Commission (SEC), the Financial Industry Regulatory Authority, Inc. (FINRA), any other federal or any state securities or other regulatory authority and therefore does not provide investing advice or investment recommendations. This communication should not be used as a basis for making any investment. Investing is inherently risky. You must be aware of the risks and be willing to accept them in order to invest in any type of security, including the risk of losing your entire investment. This message is neither a solicitation nor an offer to buy or sell securities. No representation is being made that any stock trade will or is likely to achieve profits. Comparisons made to other featured companies or past performance are not indicative of future results.
The markets and trends that matter, made simple.
Join 100,000 investors reading The New Money
Research, not investment advice.